Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot aims to ease anxiety and depression in cannabis users

NCT ID NCT06920238

Symptom relief Sponsor: Trustees of Dartmouth College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether a generative AI chatbot called Therabot-CALM is usable and acceptable for people with cannabis use disorder who also have anxiety or depression. Fifteen participants will use the app for 4 weeks and give feedback through interviews and surveys. The goal is to see if the app is feasible and liked, not yet to prove it improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Therabot-CALM (a generative AI chatbot mobile app)
What this could lead to
If this works, it could point toward a new, accessible way to help people with cannabis use disorder manage anxiety and depression using a smartphone app.
What could go wrong
This is a very early, small phase 1 trial with only 15 people, focused on feasibility and usability—not on proving the app works. The app may not be effective, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Started

Apr 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is 18 years or older. * Meet criteria for current CUD (CUDIT-R\>=12) and MDD (PHQ-9\>=10), and/or GAD (GAD-7\>=10). * Have reliable access to the internet and a compatible device for Therabot-CALM. * Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study. * Attend the first interview. Exclusion Criteria: * Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires. * Current psychosis (as determined by brief psychosis screen). * Current participation in another digital mental health intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder cannabis dependence Depression generalized anxiety disorder major depressive disorder mixed anxiety and depressive disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Cannabis use disorder Depression - major depressive disorder Depression, anxiety

Contacts and locations

Locations

  • 46 Centerra Parkway, Suite 300, Office #333S

    Lebanon, New Hampshire, 03766, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.